SEC Form 4 · accession 0001493152-26-029137
Oncotelic Therapeutics, Inc. · OTLC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Vuong Trieu
Officer — CHAIRMAN AND CEO · Director · 10% Owner
Period of report
Jun 15, 2026
Accepted (ET)
Jun 17, 2026 · 7:34 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000908259
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 17, 2026 | P | 239,759 | $0.0446 | A | 93,629,319 | D | |
| Common Stock | Jun 15, 2026 | P | 96,000 | $0.045 | A | 93,389,560 | D | |
| Common Stock | holding | — | — | — | 16,780,384 | I | By Autotelic Inc. | |
| Common Stock | holding | — | — | — | 6,872,529 | I | By spouse |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On June 15, 2026, Dr. Vuong Trieu purchased 96,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.05. Further, on June 17, 2026, Dr. Vuong Trieu purchased 239,759 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.0446.